ATE477812T1 - Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit - Google Patents

Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit

Info

Publication number
ATE477812T1
ATE477812T1 AT03705492T AT03705492T ATE477812T1 AT E477812 T1 ATE477812 T1 AT E477812T1 AT 03705492 T AT03705492 T AT 03705492T AT 03705492 T AT03705492 T AT 03705492T AT E477812 T1 ATE477812 T1 AT E477812T1
Authority
AT
Austria
Prior art keywords
obesity
whey protein
tryptophan
protein hydrolysates
rich peptides
Prior art date
Application number
AT03705492T
Other languages
English (en)
Inventor
Marjoleine Maria Theodora Gerarda Bartels-Arntz
Johannes Steijns
Petronella Caessens
Original Assignee
Campina Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32844952&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE477812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Campina Bv filed Critical Campina Bv
Application granted granted Critical
Publication of ATE477812T1 publication Critical patent/ATE477812T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03705492T 2003-02-07 2003-02-07 Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit ATE477812T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2003/000084 WO2004069265A1 (en) 2003-02-07 2003-02-07 Use of tryptophan rich peptides

Publications (1)

Publication Number Publication Date
ATE477812T1 true ATE477812T1 (de) 2010-09-15

Family

ID=32844952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705492T ATE477812T1 (de) 2003-02-07 2003-02-07 Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit

Country Status (9)

Country Link
US (2) US7582601B2 (de)
EP (1) EP1599215B1 (de)
JP (1) JP4611752B2 (de)
AT (1) ATE477812T1 (de)
AU (1) AU2003207417A1 (de)
DE (1) DE60333868D1 (de)
DK (1) DK1599215T3 (de)
ES (1) ES2350310T3 (de)
WO (1) WO2004069265A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE349918T1 (de) * 2002-07-01 2007-01-15 Unilever Nv Zusammensetzung, die ein sättigungsgefühl hervorruft
WO2005117933A1 (en) * 2004-05-27 2005-12-15 Campina Nederland Holding B.V. Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition
DE102004040452A1 (de) * 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
DK1831361T3 (da) 2004-12-23 2012-05-14 Campina Nederland Holding Bv Proteinhydrolysat beriget med peptider, som inhiberer DPP-IV, og deres anvendelse
ES2350907T3 (es) * 2005-07-01 2011-01-28 N.V. Nutricia Nutrición para bebés con proteínas hidrolizadas.
US8431531B2 (en) 2005-11-30 2013-04-30 Campina Nederland Holding B.V. Methods for stimulating glucagon-like peptide-1(GLP-1) secretion and treatments comprising same
ES2382910T3 (es) 2006-11-02 2012-06-14 Dsm Ip Assets B.V. Uso de hidrolizados de lisozima que contienen triptófano
US7989007B2 (en) * 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
JP2010532660A (ja) 2007-07-06 2010-10-14 ディーエスエム アイピー アセッツ ビー．ブイ． 食物組成物
EP2282641B1 (de) * 2008-04-29 2012-08-29 DSM IP Assets B.V. Zusammensetzung mit kohlenhydraten und peptiden die tryptophan enthalten
AU2009262338A1 (en) * 2008-06-26 2009-12-30 Healthlinx Limited Protocols for treating and preventing obesity and complications arising therefrom
JP5735734B2 (ja) * 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
CN103153326B (zh) * 2010-10-05 2015-08-19 帝斯曼知识产权资产管理有限公司 含有色氨酸的肽
US20140050715A1 (en) 2011-04-28 2014-02-20 Dsm Ip Assets B.V. Protein hydrolysates as agents for overcoming addiction
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
CN105992520A (zh) * 2013-12-19 2016-10-05 雅培公司 包含水解蛋白质的营养组合物
ES2841939T3 (es) 2015-03-30 2021-07-12 Nestle Sa Hidrolizados de proteínas a base de leche y composiciones elaboradas mediante éstos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8523338D0 (en) * 1985-09-20 1985-10-23 Kreitzman S N Treatment of obesity
US6013622A (en) * 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US6838431B2 (en) * 1999-07-27 2005-01-04 Pacific Health Laboratories, Inc. Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety
AU2001228921A1 (en) * 2000-12-06 2002-06-18 Campina Melkunie B.V. Method for preparing tryptophan rich peptides
US6429190B1 (en) * 2000-12-15 2002-08-06 Pacifichealth Laboratories, Inc. Method for extending the satiety of food by adding a nutritional composition designed to stimulate cholecystokinin(CCK)

Also Published As

Publication number Publication date
DK1599215T3 (da) 2010-11-15
US7582601B2 (en) 2009-09-01
ES2350310T3 (es) 2011-01-21
WO2004069265A1 (en) 2004-08-19
JP4611752B2 (ja) 2011-01-12
US20100087359A1 (en) 2010-04-08
DE60333868D1 (de) 2010-09-30
EP1599215B1 (de) 2010-08-18
JP2006514083A (ja) 2006-04-27
EP1599215A1 (de) 2005-11-30
US20060257497A1 (en) 2006-11-16
AU2003207417A1 (en) 2004-08-30

Similar Documents

Publication Publication Date Title
ATE477812T1 (de) Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
DE60305055D1 (de) Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten
DK1261360T3 (da) Casein-afledte peptider og anvendelser deraf i behandling
DE602004023210D1 (de) Biologisch nicht-abbaubares peptid, inhibitor des angiotensinumwandelnden enzyms, arzneimittel und funktionelles nahrungsmittel
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
ATE496060T1 (de) Proteinartige verbindungen und anwendungen davon
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
ATE349538T1 (de) Collectin-komplement aktivierende proteinchimären
DE60213648D1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
DE60309513D1 (de) Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
EA202191753A1 (ru) Синтетические и рекомбинантно полученные коллагеновые пептиды, имеющие биологическую активность
DK0838473T3 (da) Peptid til inhibering af blodtriglyceridkoncentrationsstigning og inhibitor for blodtriglycerid-koncentrationsstigning omfattende peptidet som aktiv bestanddel
KR960701089A (ko) 지방세포 분화 억제 펩타이드 및 그를 유효성분으로 포함하는 지방세포 분화 억제제
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ATE391510T1 (de) Verwendung eines lupinkonglutins für die behandlung von diabetes typ ii
WO2005023896A3 (en) Purified polyoxypropylene/polyoxyethylene copolymers and method of preparing the same
DE60030787D1 (de) Verwendung von l-carnitin als stabilitsator für proteine
ATE454896T1 (de) Heilkräuterzusammensetzung zur behandlung von aids
JP2001213792A5 (de)
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1599215

Country of ref document: EP